Native peptides suffer from rapid degradation and poor bioavailability. Modern engineering has developed multiple strategies to overcome these limitations.
The Problem: Why Peptides Need Stabilization
- **Proteolytic degradation** — Peptidases rapidly cleave peptide bonds
- **Renal clearance** — Small size allows kidney filtration
- **Poor membrane permeability** — Hydrophilic nature limits cell entry
- **Conformational instability** — Lack of stable structure
Chemical Modifications
D-Amino Acids - Mirror images of natural L-amino acids - **Not recognized** by most proteases - Example: D-amino acid substitutions in semaglutide
N-Methylation - Blocks hydrogen bonding at peptide backbone - Prevents protease recognition - Reduces flexibility
Non-Natural Amino Acids - α-methyl amino acids resist proteolysis - β-amino acids change backbone geometry - Dehydro-amino acids add rigidity
Structural Constraints
Cyclization - **Head-to-tail** — Connect N and C termini - **Disulfide bonds** — Cysteine cross-links - **Lactam bridges** — Side chain connections - Example: Cyclosporin A (cyclic 11-mer, orally bioavailable)
Peptide Stapling Uses hydrocarbon linkers to lock α-helical structure: - Positions i, i+4 or i, i+7 connected - Ring-Closing Metathesis (RCM) forms staple - Provides: - Structural rigidity - Protease resistance - Cell permeability
Example: ALRN-6924 (stapled p53 peptide)
Half-Life Extension
Lipidation (Albumin Binding) - Fatty acid attached to peptide - Binds serum albumin (66 kDa, long half-life) - **Hijacks FcRn recycling pathway** - Example: Semaglutide uses C18 fatty diacid
PEGylation - Polyethylene glycol chains attached - Increases hydrodynamic radius - Prevents renal filtration - Reduces immunogenicity
Fc-Fusion - Peptide fused to antibody Fc region - Exploits FcRn-mediated recycling - Example: Romiplostim (thrombopoietin mimetic)
XTEN Technology - Fusion to unstructured protein polymer - Increases molecular weight - Biodegradable
Half-Life Comparison
| Peptide | Native Half-Life | Extended Half-Life | Strategy |
|---|---|---|---|
| GLP-1 | ~2 min | ~1 week (semaglutide) | Lipidation |
| Exendin-4 | ~2.5 hr | ~1 week (dulaglutide) | Fc-fusion |
| Insulin | ~5 min | ~24 hr (glargine) | Crystal engineering |
Combining Strategies
Modern peptide drugs often combine multiple approaches:
- D-amino acids (resist DPP-IV)
- Aib substitution (stabilize helix)
- C18 lipidation (albumin binding)
- Result: Once-weekly dosing